Introduction
Symptomatic cardiac metastases from primary transitional cell carcinoma (TCC) are uncommon, and cases where the presenting complaint is directly attributable to the cardiac metastasis with subsequent discovery of the primary tumour are rare. Such cases pose considerable clinical challenges and the optimum management is unclear. We report the first successful one-stage nephrectomy and debulking of cardiac metastasis from TCC in a 58-year-old female patient.
Case summary
A 58-year-old female secretary presented to her GP in May 2010 complaining of a five-month history of malaise, anorexia and 3 kg weight loss and a two-month history of worsening shortness of breath on exertion, palpitations, light-headedness and night sweats. She had a single brief episode of haematuria four months previously. She was referred to the Cardiology Department at King's College Hospital, London for investigation of suspected infective endocarditis.
Her medical history included hypothyroidism controlled with 150 mg thyroxine daily and a 15 pack-year smoking history. On examination, the patient was apyrexial, had no peripheral stigmata of infective endocarditis, however, on auscultation, a loud, pan-systolic murmur was audible, loudest at the lower left sternal edge.
A transthoracic echocardiogram (Fig. 1a) septum and abutting the pulmonary valve. The mass was causing significant obstruction to the right ventricular outflow tract. A ventricular myxoma was suspected, however, computed tomography (CT)-scan of the chest, abdomen and pelvis confirmed a right ventricular filling defect (Fig.  1b and c) and two sub-centimetre nodules in the lower lobe of the right lung and a large 80=76 mm heterogeneous infiltrative mass at the upper pole of the left kidney, subsequently confirmed by magnetic resonance imaging (MRI) ( Fig. 1d and e) . Cardiac catheterisation demonstrated no compromise of coronary artery blood flow.
Our cardiothoracic and urological surgeons agreed a multidisciplinary, concurrent, one-stage removal of the right ventricular mass and radical left nephrectomy. Surgical access to the right ventricle was gained via a median sternotomy, bicaval to ascending aortic bypass at 288 and a transverse incision in the right atrium. Before accessing the mass via the tricuspid valve, the pulmonary artery was cross-clamped to prevent embolisation to the lungs. The tumour was strongly adherent to the intraventricular septum and tumour debulking from interventricular septum was performed leaving it intact ( Fig. 1f and g ). A radical left nephrectomy was performed following closure of the sternotomy.
Histopathology confirmed a 90=80=50-mm variegated, grade III TCC with sarcomatoid differentiation infiltrating the renal parenchyma and perinephric fat. Areas of coagulative necrosis and cystic change were noted (Fig. 2a-c) . Metastatic deposits were found in the 3y7 of the local nodes, however the renal vein, left adrenal gland and resection margins were clear of tumour. The right ventric- Fig. 1 . Echocardiographic, CT and MRI and intraoperative images of cardiac metastasis and primary tumour: echocardiogram of the cardiac metastasis abutting the pulmonary valve (a). Axial (b) and coronal (c) contrast enhanced CT images of the metastatic tumour causing a filling defect in the right ventricle. Axial (d) and coronal (e) contrast enhanced T1 MRI images of the primary renal tumour. Photographs show metastatic tumour occupying the right ventricle, adherent to the intraventricular septum before (f) and after (g) tumour debulking. CT, computed tomography; MRI, magnetic resonance imaging. ular mass was found to be metastatic TCC with focal squamoid and sarcomatoid differentiation (Fig. 2d) . The tumour was staged pT4 pN2 pM1.
The patient made a remarkably swift and uneventful postoperative recovery. She was discharged home 14 days postoperatively with a referral to the oncology team who commenced adjuvant gemcitabine and cisplatin chemotherapy. On nine-week postoperative outpatient follow-up, her performance status is zero and she reports no cardiorespiratory symptoms.
Discussion
TCC of the renal pelvis accounts for only 5% of urothelial tumours and has an incidence of 0.7-1.1 per 100,000 population with a 1.7:1 male to female bias w1x. Risk factors for TCC include smoking, analgesic nephropathy and occupational exposure to petrochemicals. Gross tumour pathology characteristically demonstrates a highly infiltrative mass destroying the renal parenchyma w1x. Patients tend to present with flank pain and haematuria and five-year survival has been reported as 100%, 91.7%, 72.6% and 40.5% for Ta, T1, T2 and T3 tumours, respectively w1x.
Cardiac metastases are found in 2.3-18.3% of disseminated cancer cases at autopsy, most commonly arising from malignant melanoma and primary mediastinal tumours w2x. Such metastases are clinically under-recognised and usually asymptomatic. Fourteen cases of symptomatic cardiac metastases from TCC have been reported in the literature, four arising from tumours of the renal pelvis. TCC cases where the presenting complaints (e.g. dyspnoea, dizziness) are directly attributable to cardiac metastases are exceptionally rare, with only three cases reported, two of which had primaries arising in the renal pelvis w3, 4x. Cardiac metastasis from TCC of the renal pelvis may be more likely to present in this manner; TCC of the upper urinary tract are, on average, more invasive and of higher grade at presentation compared to TCC of the bladder w5x.
Optimum management of TCC with cardiac metastasis is unclear. Of the cases reported in the literature, the vast majority of patients have died within weeks of diagnosis. Resection of cardiac metastases was attempted in two cases but survival did not exceeded four weeks w6, 7x. Gemcitabine-carboplatin based chemotherapy has been used for palliation of cardiac metastases in two cases with some success; one patient remained asymptomatic for over one year with a 40% reduction in cardiac tumour size and another demonstrated performance status improvement from three to zero for seven months before subsequent deterioration w8, 9x.
One-stage surgical management of cardiac and renal pathology have been successfully employed to treat renal cell carcinomas with concomitant tumour infiltration of the inferior vena cava, pulmonary artery tumour embolisation, or multi-vessel coronary artery disease w10x. One-stage approaches are hypothesised to reduce ventilation duration and hospital stay over two-stage approaches w10x, and although concern has been raised that post-bypass immunosuppression may contribute to subsequent metastatic tumour growth, no evidence currently supports this hypothesis. In conclusion, cardiac metastasis from TCC poses considerable clinical challenges. We report that one-stage nephrectomy and cardiac surgery can be successfully employed to extend lifespan and improve quality of life for such patients.
